Roche Holding AG RHHBY
59.37 USD -0.08 (-0.13%)
At closeNov 6, 2026, 4:00 PM EST
58.22 Day range 59.61
41.22 52-week range 61.27
- YTD
- +15.13%
- 1 year
- +44.03%
News
prnewswire.com Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs The new cobas ® eplex RP3 panel detects up to 19 viruses and bacteria, with newly added Bordetella pertussis and improved inclusivity of influenza A and SARS-CoV-2 strains, from a single sample to…
benzinga.com Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’sZymeworks will conduct the Phase 1a monotherapy…
benzinga.com Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts Roche halts German investments as chief Daniel Steiners warns Berlin that statutory drug rebates shatter trust in the market.
benzinga.com Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy Roche earns FDA approval for Enspryng in thyroid eye disease, offering the only at-home subcutaneous treatment for TED.- benzinga.com Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of…
benzinga.com Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine Merck reports Phase 2b/3 BRUNELLO trial data for remigromig in DME, achieving vision non-inferiority to ranibizumab alongside elevated adverse event rates.
benzinga.com Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating primary IgA nephropathy.
benzinga.com Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney…
benzinga.com Roche Receives EMA CHMP Recommendation Of Approval Ocrevus For Pediatric Patients With Relapsing Forms Of Multiple Sclerosis The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future."Children and teens living with multiple sclerosis…
benzinga.com The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.
benzinga.com IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS…
benzinga.com Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.
benzinga.com Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market Nurix Therapeutics and Roche sign a BTK degrader partnership worth up to $2.3 billion, supporting Phase 3 plans for bexobrutideg.- benzinga.com Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential…
benzinga.com IDEAYA Enters Collaboration With Roche To Evaluate The Efficacy And Safety Of IDE892, Its Investigational PRMT5 Inhibitor, With Roche's RG6505 IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1…
benzinga.com EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates…
benzinga.com Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
benzinga.com C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.- benzinga.com C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new…
benzinga.com 'Roche Restricts Consulting Work With Big Four Firms To Cut Costs' - Bloomberg https://www.bloomberg.com/news/articles/2026-03-24/roche-restricts-consulting-work-with-big-four-firms-to-cut-costs?utm_source=latest&utm_medium=share&utm_campaign=copy
benzinga.com Viking Therapeutics Stock Gains Amid Obesity Drug Buzz Viking shares rise after Novo's REDEFINE 4 trial trails Lilly's tirzepatide in weight loss.
benzinga.com FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer FDA approves AbbVie's all-oral leukemia treatment combo, showing better three-year outcomes and offering patients a chance for time off therapy compared to standard chemo.
benzinga.com Sarepta Says Elevidys Slows Duchenne Progression After Three Years Sarepta's Elevidys shows significant improvement in motor function measures after three years of treatment, with no new safety signals.
benzinga.com What's Going On With Royalty Pharma Stock Wednesday? Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
benzinga.com Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.
benzinga.com Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
benzinga.com Two Biotech Stocks Poised For Big Moves On Monday 
benzinga.com 'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease#:~:text=The%20Lumipulse%20G%20pTau217%2F%C3%9F,and%20symptoms%20of%20the%20disease.- benzinga.com United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains.
- benzinga.com Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
- benzinga.com The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday - benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
benzinga.com Stocks That Hit 52-Week Highs On Tuesday - benzinga.com Stocks That Hit 52-Week Highs On Friday
benzinga.com Stocks That Hit 52-Week Highs On Thursday - benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Friday
- benzinga.com Stocks That Hit 52-Week Highs On Friday
- benzinga.com Stocks That Hit 52-Week Highs On Monday
- benzinga.com Stocks That Hit 52-Week Highs On Friday
- benzinga.com Stocks That Hit 52-Week Highs On Thursday
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com 2 New ETFs Worth A Gander